EliA assays combine exceptional specificity with the highest sensitivity, and provide the guidance and safety clinicians need for their day-to-day diagnostic decisions. Most importantly, the excellence of the positive predictive values and likelihood ratios of our EliA assays assure high clinical usefulness in routine practice.
- “Phadia EliA dsDNA assay provides the best specificity, positive predictive value and post-test probability in the study.”
Antico, Lupus 2010
- “…. a positive result by EliA CTD Screen had a higher likelihood ratio than does a positive result by indirect immunofluorescence.”
Op de Beeck, Autoimmun Rev 2011
- “… IgA anti-tTG assay from Phadia had the highest likelihood ratio in this study.”
Vermeersch P., Clin Chim Acta 2010
- “Importantly, positive predictive values of the automated tests (85.2%) in comparison to the CCP IgG 3.0 manual ELISA (72.5%) resulted in a better correlation with clinical RA.”
Elfrefaei, J.Clin. Immunol. 2011
For many tests, quantitative results enable estimations of the severity and prognosis of the disease. Quantitative results therefore have a higher clinical value than do qualitative results, which indicate only whether the test result is positive or negative.
Offering doctors specific markers (e.g. EliA dsDNA) appropriate to follow-up supports them in their patient management.
- "Follow-up of SLE patients with nephritis showed good correlation between flare and dsDNA antibodies by EliA dsDNA."
Poster Viander M. et al. 5th International Congress on Autoimmunity, Sorrento, Nov. 2006
- "EliA dsDNA detects anti-dsDNA antibodies in patients with renal involvement more frequently and with a significantly higher mean titer compared to patients without this complication."
Vilalta D. et al., J Clin Lab Anal 2002, 16: 227-232